Evaluation of bortezomib induced neuropathy using Total Neuropathy Score (reduced and clinical versions) and NCI CTCAE v4.0 in newly diagnosed patients with multiple myeloma receiving bortezomib-based induction

Conclusions NCI-CTCAE may be suboptimal in comparison to TNSr and TNSc in assessment of BiPN as it may miss worsening neuropathy without functional limitation. Teaser Total Neuropathy Score (TNS) (reduced and clinical versions) is ideal for evaluation of bortezomib induced neuropathy. We used TNSr and TNSc along with NCI CTCAE v4.0 to assess incidence of neuropathy in patients receiving CyBorD as induction for multiple myeloma. Out of 20 evaluable patients, 55%, 40% and 45% developed neuropathy when assessed by TNSr, TNSc and NCI CTCAE respectively. We found wide variation in TNSr and TNSc even when NCI CTCAE scale reported no progression of neuropathy.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research